Diffuse intrinsic pontine gliomas (DIPG) are inoperable and highly resistant to chemo- and radiation therapy. DIPG carry the worst prognosis among pediatric brain tumors with progress in the development of therapies compromised by low patient numbers and unavailability of tissue samples to characterize disease status. In this work we present evidence, that non-invasive MR spectroscopy can provide robust early indicators that can assess the effectiveness (or ineffectiveness) of potential new therapeutic approach at an early stage and accelerate the completion of clinical trials in small cohorts of patients.
This abstract and the presentation materials are available to members only; a login is required.